First Patients Enrolled in IMPRoVED-AF Study Using vMap, a Non-Invasive ECG-Based Tool Designed to Guide More Effective AF Ablation
With growing pressure to improve outcomes and reduce re-do procedures, physicians and hospitals are seeking non-invasive tools that can improve targeting while maintaining necessary workflow efficiencies. vMap is designed to address this need...
Share
IMPRoVED-AF is a prospective, randomized, controlled, international, multi-center study designed to rigorously compare clinical outcomes in patients undergoing pulmonary vein isolation (PVI) alone versus PVI and additional driver ablation guided by vMap®, the only FDA-cleared non-invasive arrhythmia analysis technology designed to improve, enhance, and accelerate ablation procedures, utilizing data from a standard 12-lead ECG. The study aims to demonstrate the comparative clinical benefit of using vMap to identify and ablate non-pulmonary vein electrical drivers, when used alongside standard-of-care ablation techniques, including advanced technologies such as pulsed field ablation (PFA), in patients with persistent and recurrent atrial fibrillation (AF).
'Enrolling the first patient in the IMPRoVED-AF study marks an important milestone in our ongoing efforts at Baptist Health to further advance care for our patients suffering from cardiac arrhythmias,' said Dr. Gery Tomassoni, Principal Investigator and cardiac electrophysiologist at Baptist Health Lexington. 'For patients with persistent and recurrent AF, treatment has often been ineffective due to the inability to identify the source of the arrhythmia. Using vMap to determine a targeted ablation strategy beyond the pulmonary veins provides an opportunity to target drivers that were previously undetectable. That means better care and more effective, lasting results for patients.'
With growing pressure to improve outcomes and reduce re-do procedures, physicians and hospitals are seeking non-invasive tools that can improve targeting while maintaining necessary workflow efficiencies. vMap is designed to address this need by delivering rapid analysis and insights from a standard 12-lead ECG.
'The IMPRoVED-AF study is an important validation of the meaningful impact vMap is already delivering in the EP lab,' said Rob Krummen, CEO of Vektor Medical. 'This isn't about incremental improvement; it's a leap forward in how we identify and treat complex arrhythmias. vMap is uncovering drivers that often go undetected, helping physicians deliver more effective and durable outcomes. This study is a critical part of our strategy to build the clinical evidence that drives confident adoption, supports value in health systems, and positions vMap as the new standard in arrhythmia care.'
The IMPRoVED-AF study, managed by Veranex, a global leader in clinical research, will enroll up to 384 patients with persistent and recurrent AF at approximately 20 electrophysiology centers across the United States and Europe. The primary endpoint of the study is freedom from AF at 12 months.
To learn more about the IMPRoVED-AF study, explore vMap technology, or request a clinical or strategic briefing, visit www.vektormedical.com and connect with us on LinkedIn and X.
About vMap®
vMap is the only FDA-cleared, non-invasive solution that transforms data from a standard 12-lead ECG into actionable insights to guide arrhythmia care. The technology, developed with AI, localizes arrhythmia source locations across all four chambers of the heart — including both focal and fibrillation-type arrhythmias. vMap is used by electrophysiologists during triage, procedural planning, and ablation to help identify and target arrhythmia drivers more quickly and with greater confidence. Backed by growing clinical evidence, use of vMap has been associated with improved outcomes, reduced procedure time, and streamlined workflow across the arrhythmia care continuum.
About Vektor Medical
Headquartered in San Diego, Vektor Medical is redefining how arrhythmias are understood and treated. The company developed vMap®, the only FDA-cleared, non-invasive technology that uses standard 12-lead ECG data to localize arrhythmia source locations across all four chambers of the heart. By helping physicians identify arrhythmia drivers more quickly and with greater accuracy, Vektor is working to improve outcomes, enhance efficiencies, and accelerate access to effective treatment strategies. To learn more, visit www.vektormedical.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Aspect Biosystems Presents New Preclinical Data on Adrenal Bioprinted Tissue Therapeutics at ENDO 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)--Aspect Biosystems, a biotechnology company pioneering the development of Bioprinted Tissue Therapeutics (BTTs) as a new category in regenerative medicine, today announced new preclinical data at ENDO 2025, the Endocrine Society's annual meeting held in San Francisco. The company presented an oral and poster presentation highlighting that Aspect's adrenal BTTs can restore adrenal function, following natural daily hormone rhythms and maintaining long-term performance in animal models of primary adrenal insufficiency. Primary adrenal insufficiency is a serious, life-threatening condition in which the adrenal glands fail to produce sufficient levels of essential hormones such as cortisol, a key regulator of the body's stress response. The current standard of care involves daily hormone replacement therapy, which does not fully replicate the body's natural circadian hormone rhythms and is associated with significant drug-related side effects. This can leave patients with a poor quality of life and at risk of ongoing health challenges, including potentially fatal adrenal crises. Aspect's adrenal BTTs were developed using the company's proprietary full-stack tissue therapeutic platform, which combines AI-powered bioprinting, computational design tools, therapeutic cells, and advanced biomaterials. In preclinical studies, adrenal BTTs containing human adrenal cells were implanted into adrenalectomized mice. These BTTs produced cortisol in response to adrenocorticotropic hormone (ACTH) stimulation—which is normally secreted from the brain—and followed the animals' natural circadian fluctuations in hormone levels. When exposed to high levels of injected ACTH, these mice demonstrated rapid increases in circulating cortisol, confirming that the adrenal BTTs were functionally responsive. In contrast, control animals receiving cell-free implants showed no significant cortisol levels and did not respond to ACTH stimulation. Importantly, adrenal BTTs remained functional in vivo throughout the study period of over six months and improved animal survival. 'Our research shows that Aspect's adrenal BTTs successfully replicate healthy human adrenal gland function by releasing cortisol in a pattern that follows the natural daily rhythms of hormone release and by responding appropriately to a stimulus that mimics a stress response,' said Sam Wadsworth, PhD, Chief Scientific Officer at Aspect Biosystems. 'These results demonstrate that our off-the-shelf, implantable cell therapy can work in harmony with the body's physiology and has real potential to serve as a functional cure for primary adrenal insufficiency." 'At Aspect, we're making breakthrough progress with our Bioprinted Tissue Therapeutics platform to restore complex biological functions across a range of serious endocrine and metabolic diseases,' said Tamer Mohamed, Chief Executive Officer of Aspect Biosystems. 'This latest advance in primary adrenal insufficiency, a rare and life-threatening condition with limited treatment options, showcases the potential of a bioengineered cell therapy to recreate natural hormone function and deliver a truly disease-modifying solution. This reflects our mission to develop regenerative medicines capable of achieving functional cures for patients with serious and underserved diseases.' About ENDO Hosted by the Endocrine Society, ENDO is the leading global meeting on endocrinology research and clinical care. The Endocrine Society is the world's oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions. Learn more at About Aspect Biosystems Aspect Biosystems is a biotechnology company pioneering the development of Bioprinted Tissue Therapeutics (BTTs) to transform how we treat some of the most elusive diseases. Aspect's BTTs are designed to replace, repair, or supplement biological function inside the body. Aspect is creating these next-generation cell therapies by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials. Aspect is advancing a pipeline of BTTs across multiple disease areas in the endocrine and metabolic space including diabetes, obesity, rare endocrine disorders, and liver disease. Aspect's pipeline development strategy involves both proprietary programs as well as strategic partnerships, including a collaboration with Novo Nordisk focused on diabetes and obesity. For more information, please visit and follow on LinkedIn.
Business Wire
an hour ago
- Business Wire
Rocket Lab Announces Date of Second Quarter 2025 Financial Results
LONG BEACH, Calif.--(BUSINESS WIRE)--Rocket Lab Corporation (Nasdaq: RKLB) ('Rocket Lab' or 'the Company'), a global leader in launch services and space systems, today announced that it will release its financial results for the second quarter 2025 following the close of the U.S. markets on Thursday August 7, 2025. Rocket Lab will host a corresponding conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live webcast and replay of the conference call will be available on the Company's Investor Relations website at About Rocket Lab Founded in 2006, Rocket Lab is an end-to-end space company with an established track record of mission success. We deliver reliable launch services, satellite manufacture, spacecraft components, and on-orbit management solutions that make it faster, easier, and more affordable to access space. Headquartered in Long Beach, California, Rocket Lab designs and manufactures the Electron small orbital launch vehicle, a family of flight proven spacecraft, and the Company is developing the large Neutron launch vehicle for constellation deployment. Since its first orbital launch in January 2018, Rocket Lab's Electron launch vehicle has become the second most frequently launched U.S. rocket annually and has delivered 200+ satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. Rocket Lab's family of spacecraft have been selected to support NASA missions to the Moon and Mars, as well as the first private commercial mission to Venus. Rocket Lab has three launch pads at two launch sites, including two launch pads at a private orbital launch site located in New Zealand and a third launch pad in Virginia. To learn more, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward looking statements contained in Section 27A of the Securities Act of 1933, as amended (the 'Securities Act') and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our launch and space systems operations, launch schedule and window, safe and repeatable access to space, Neutron development, operational expansion and business strategy are forward-looking statements. The words 'believe,' 'may,' 'will,' 'estimate,' 'potential,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'strategy,' 'future,' 'could,' 'would,' 'project,' 'plan,' 'target,' and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to the factors, risks and uncertainties included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the 'SEC'), accessible on the SEC's website at and the Investor Relations section of our website at which could cause our actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Business Wire
2 hours ago
- Business Wire
Auna Announces Reporting Dates for Second Quarter 2025 Financial Results
LUXEMBOURG--(BUSINESS WIRE)-- Auna S.A. (NYSE: AUNA) ('Auna' or 'the Company'), a leading Latin American healthcare services and plan provider with operations in Mexico, Peru and Colombia, announced today the reporting dates for its Second Quarter 2025 financial results. Earnings Release Tuesday, August 19, 2025 Time: After Market Close Conference Call Wednesday, August 20, 2025 Time: 8:00 a.m. ET Quiet Period Monday, August 4 through Tuesday, August 19, 2025 To participate, please dial +1 888 596 4144 (Toll-Free) +1 646 968 2525 (International) Entry Passcode: 3884034 Webcast: click here About Auna Auna is a leading horizontally and vertically integrated healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, focusing on high-complexity diseases. Our mission is to transform healthcare by providing access to a highly integrated healthcare offering in the underpenetrated markets of Spanish-speaking Americas. Founded in 1989, Auna has built one of Latin America′s largest modern healthcare platforms that consists of a horizontally integrated network of healthcare facilities and a vertically integrated portfolio of oncological plans and selected general healthcare plans. As of March 31st, 2025, Auna's network included 31 healthcare network facilities, including hospitals, outpatient, prevention and wellness facilities with 2,323 beds, and 1.4 million healthcare plans. For more information visit
